RT Journal Article
T1 Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer.
A1 Cattrini, Carlo
A1 Soldato, Davide
A1 Rubagotti, Alessandra
A1 Zinoli, Linda
A1 Zanardi, Elisa
A1 Barboro, Paola
A1 Messina, Carlo
A1 Castro, Elena
A1 Olmos, David
A1 Boccardo, Francesco
K1 SEER Program
K1 Prostatic neoplasms
K1 Mortality
K1 Epidemiology
AB The real-world outcomes of patients with metastatic prostate cancer (mPCa) are largely unexplored. We investigated the trends in overall survival (OS) and cancer-specific survival (CSS) in patients with de novo mPCa according to distinct time periods. The U.S. Surveillance, Epidemiology, and End Results (SEER) Research Data (2000-2017) were analyzed using the SEER*Stat software. The Kaplan-Meier method and Cox regression were used. Patients with de novo mPCa were allocated to three cohorts based on the year of diagnosis: A (2000-2003), B (2004-2010), and C (2011-2014). The maximum follow-up was fixed to 5 years. Overall, 26,434 patients were included. Age, race, and metastatic stage (M1) significantly affected OS and CSS. After adjustment for age and race, patients in Cohort C showed a 9% reduced risk of death (hazard ratio (HR): 0.91 (95% confidence interval [CI] 0.87-0.95), p< 0.001) and an 8% reduced risk of cancer-specific death (HR: 0.92 (95% CI 0.88–0.96), p < 0.001) compared with those in Cohort A. After adjustment for age, race, and metastatic stage, patients in Cohort C showed an improvement in OS and CSS compared with Cohort B (HR: 0.94 (95% CI 0.91–0.97), p = 0.001; HR: 0.89 (95% CI 0.85–0.92), p < 0.001). Patients with M1c disease had a more pronounced improvement in OS and CSS compared with the other stages. No di erences were found between Cohorts B and C. In conclusion, the real-world survival of de novo mPCa remains poor, with a median OS and CSS improvement of only 4 months in the latest years.
PB MDPI
SN 2072-6694
YR 2020
FD 2020-10-03
LK https://hdl.handle.net/10668/27085
UL https://hdl.handle.net/10668/27085
LA en
NO Cattrini C, Soldato D, Rubagotti A, Zinoli L, Zanardi E, Barboro P, et al. Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer. Cancers (Basel). 2020 Oct 3;12(10):2855
DS RISalud
RD Apr 17, 2025